Apollo invests Rs 40 Cr to construct Lymphedema Clinic for girls’s healthcare
August 11, 2026 | Tuesday | Information
A primary-of-its-kind multidisciplinary programme brings world requirements of lymphatic care to India
Apollo Athenaa, Asia’s first devoted girls most cancers centre by Apollo Hospitals, has introduced the launch of India’s first one cease complete Lymphedema Clinic in Delhi, accredited by the Lymphatic Schooling & Analysis Community (LE&RN)—an internationally recognised non-profit organisation devoted to advancing schooling, analysis and advocacy for lymphatic illnesses—setting a brand new benchmark within the administration of cancer-related lymphedema.
Designed round internationally recognised requirements of care, the clinic brings collectively specialised surgeons, lymphedema therapists, nurses, dermatologists and rehabilitation consultants underneath a single multidisciplinary programme, providing complete care spanning prevention, early prognosis, superior microsurgery, rehabilitation and lifelong follow-up.
India is estimated to have over a million individuals residing with lymphedema. Of those, an estimated 400,000–600,000 live with cancer-related lymphedema, with 30,000–50,000 new circumstances creating yearly. As most cancers survival charges proceed to enhance, this burden is anticipated to rise, underscoring the pressing want for devoted multidisciplinary lymphedema providers.
Girls present process breast and gynaecological most cancers remedy stay among the many most weak, as lymph node elimination and radiation remedy can completely disrupt lymphatic drainage, leading to continual swelling, recurrent infections, decreased mobility and a major influence on long-term high quality of life.
As much as 20% to 42% of ladies develop arm lymphedema after breast most cancers surgical procedure, and roughly 31% to 37% of survivors of gynecological cancers expertise lower-limb lymphedema.
Regardless of this rising burden, entry to specialised multidisciplinary lymphedema care stays restricted in India, with sufferers typically navigating fragmented remedy pathways that delay intervention and compromise long-term outcomes.
